The Oncotype DX GPS Test for Unfavorable Intermediate Risk Prostate Cancer
See how men with unfavorable intermediate-risk prostate cancer can be stratified into two distinct groups with highly differing long-term outcomes. Use the GPS assay to make informed treatment decisions based on a patient’s genomic risk.